Artificial human embryos could soon be on the horizon, but what will it mean? Well, arguably the potential of such a breakthrough could herald a new biological revolution.
Direct to consumer testing can potentially be quite dangerous without appropriate regulations and support to fully understand the implications of the information a consumer receives.
A literature review finds an increased risk of cancer, late-stage cancer, and mortality, with increased waiting time between a positive screening and start of diagnostic testing.
A drug combination has been discovered that could potentially reverse disease symptoms by adjusting natural cellular functions.
23andMe CEO and co-founder Anne Wojcicki says consumers don’t need experts to interpret results from genetic risk tests, and compared the information her company offers to at-home pregnancy tests. But is it that simple?
Researchers have used CRISPR to develop a pig model of Huntington’s disease that better mimics how the disease progresses in humans.
Concerningly, 20% of publicly funded cancer clinical trials in the United States fail because investigators are unable to enroll enough participants.
Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, has secured a $60 million Series A+ financing.
With the demand for direct-to-consumer genetic tests on the rise, a new analysis has questioned how reliable the results really are.
Healthcare tech startup Theranos was riding high back in 2014. But when a reporter raised questions, its media reps circled the wagons.